Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles

Bassiouny, Yasmin A.; Dakhly, Dina M.R.; Bayoumi, Yasser; Salaheldin, Noha M.; Gouda, Hisham M.; Hassan, Ayman

doi:10.1002/ijgo.12360

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 425 articles were initially identified. After by layer screening, only 5 [14] [18] studies met criteria, including 421 women. Document screening process and results shown in Figure 1.…”

Section: Literature Retrieval Resultsmentioning

confidence: 99%

“…Subgroup analysis result showed that 0.5 mg cabergoline daily was obviously increased fertilization rate and the abortion rate was significantly lower than coasting group. One study proved that the combined administration provided better protection without notable side effects [18]. However, Hwang [19] pointed out that the efficacy of cabergoline is not good in preventing severe OHSS through two cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

Liu¹,

Wang²,

Meng³

et al. 2020

ARSci

View full text Add to dashboard Cite

Objective: To compare the effectiveness of two methods in preventing ovarian hyperstimulation syndrome (OHSS) with cabergoline and coasting. Design: Systematic review and meta-analysis of randomized clinical trials (RCTs). Patients: Women were considered as have risk of OHSS undergoing fertility treatment. Interventions: Cabergoline, coasting. Result: There were included five RCT studies. The clinical pregnancy rate was no significantly difference between two groups (RR 1.22, 95% CI [0.86, 1.71]), implantation rate (RR 1.00, 95% CI [0.75, 1.32]), severe OHSS (RR 0.93, 95% CI [0.38, 2.31]), fertilization rate (SMD 0.70, 95% CI [−0.10, 1.50]), number of oocytes retrieved (SMD 0.80, 95% CI [0.30, 1.30]), number of embryo transfer (SMD-0.04, 95% CI [−0.24, 0.17]), E 2 value on the day of HCG injection (SMD 0.21, 95% CI [−0.25, 0.68]), number of MII oocytes (SMD 0.71, 95% CI [0.32, 1.11]), abortion rate (RR 0.61, 95% CI [0.21, 1.83]), number of follicles > 17 mm on day of HCG (SMD-0.01, 95% CI [−0.26, 0.24]), number of follicles 15-17 mm on day of HCG (SMD −0.08, 95% CI [−0.33, 0.17]), number of follicles 10-14 mm on day of HCG (SMD −0.06, 95% CI [−0.31, 0.19]). Conclusion: Both cabergoline and coasting prevent the occurrence of OHSS, but no statistically significant difference between them. Compared with coasting group, a daily dose of 0.5 mg cabergoline significantly increased the number of oocytes retrieved, MII oocytes, and fertilization rate, but decreased the abortion rate.

show abstract

Section: Literature Retrieval Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

Liu¹,

Wang²,

Meng³

et al. 2020

ARSci

View full text Add to dashboard Cite

show abstract

“…Some studies showed that vaginal administration of bromocriptine could reduce the probability of adverse reactions in the digestive tract and nervous system, and has a preventive effect on OHSS (15). Bromocriptine as dopamine receptor agonists is currently often used for the OHSS prevention (21). Spitzer, D., et al (22)found that bromocriptine and cabergoline have similar OHSS preventive effects.…”

Section: Introductionmentioning

confidence: 99%

Combined Treatment with Prednisone and Bromocriptine does not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles

Wang¹,

Xia²

2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in assisted reproduction technology (ART). The aim of this study was to evaluate if the combined treatment with prednisone and bromocriptine will reduce the risks of ovarian hyperstimulation syndrome (OHSS) and influence the pregnancy outcomes in fresh embryo transfer cycles. Method: Retrospective study was performed and Infertile patients undergoing assisted reproduction techniques were recruited. Results: The cancellation rate for OHSS in the combined group was 31.45%, while the control group was 40.88%. There was a significant reduction of the OHSS cancellation rate between the combined group and the control group (P<0.001). The single embryo transfer had been completed in 350 cycles in the combined group, and 495 cycles for double embryos transfer. Single embryo transfer were just only 227 cycles for the control group, while 517 cycles for double embryos transfer (P<0.001). As for the total successful embryo implantation, 509 cycles were in the combined-treated group (40.88%), while the 442 cycles in the control group which have the statistical differences between them (38.30%, P= 0.012). There was no statistical difference in clinical pregnancy rate (P=0.492), miscarriage rate(P=0.792), ongoing pregnancy rate(P=0.719), live birth rate(P=0.295), the congenital abnormalities rate (P=0.081), and the ectopic pregnancy occurrence rate(P=0.649) between the combined group and the control group. Conclusion Compared with the bromocriptine single using, combined-treated bromocriptine with prednisone can better reduce the OHSS occurrence rate dramatically and effectively and not affect the pregnancy outcomes in fresh embryo transfer cycles.

show abstract

“…Hence, bromocriptine is often used for OHSS prevention [22]. Spitzer et al [23] found that bromocriptine and cabergoline have similar OHSS preventive effects.…”

Section: Introductionmentioning

confidence: 99%

Combined Treatment With Prednisone and Bromocriptine Does Not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles: a Retrospective Study

Wang¹,

Mu²,

Qin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian hyperstimulation syndrome (OHSS) is a severe complication for infertile patients undergoing assisted reproduction technology (ART) treatment. Bromocriptine and prednisone are often used for treating OHSS. This study aimed to evaluate whether combined treatment with prednisone and bromocriptine can reduce the risk of OHSS and influence pregnancy outcomes in fresh embryo transfer cycles.Methods: This retrospective study recruited infertile patients undergoing assisted reproduction techniques. We included 4,114 cycles of infertile patients who underwent IVF or ICSI treatment between January 2014 and May 2017 and divided them into two groups: the combined-treatment group and the single-treatment group.Results: The OHSS cancellation rates in the combined- and single-treatment (control) groups were 31.50% and 40.88%, respectively. There was a significant reduction in the OHSS cancellation rate between the combined- and single-treatment groups (P<0.001). Single- and double-embryo transfers were completed in 350 and 495 cycles, respectively, in the combined-treatment group and in 227 and 517 cycles, respectively, in the single-treatment group (P<0.001). The total number of successful embryo implantation was significantly different between the combined-treatment group (509 cycles, 40.88%) and single-treatment groups (442 cycles, 38.30%) (P=0.012). There was no statistically significant difference in the clinical pregnancy (P=0.492), miscarriage (P=0.792), ongoing pregnancy (P=0.719), live birth (P=0.295), congenital abnormality (P=0.081), and ectopic pregnancy occurrence rates (P=0.649) between the combined- and single-treatment groups.Conclusion: Compared with bromocriptine alone, combined treatment with bromocriptine and prednisone can better reduce the OHSS occurrence rate and does not affect the pregnancy outcomes in fresh embryo transfer cycles.

show abstract

Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles

Abstract: Combining coasting and cabergoline was associated with a lower OHSS rate compared with either therapy alone. CLINICALTRIALS.GOV: NCT01984320.

Cited by 6 publications

References 23 publications

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

Combined Treatment with Prednisone and Bromocriptine does not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles

Combined Treatment With Prednisone and Bromocriptine Does Not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles: a Retrospective Study

Contact Info

Product

Resources

About

Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles

Abstract: Combining coasting and cabergoline was associated with a lower OHSS rate compared with either therapy alone. CLINICALTRIALS.GOV: NCT01984320.

Cited by 6 publications

References 23 publications

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

The Influence of Cabergoline and Coasting in Prevention of the Ovarian Hyperstimulation Syndrome in Patients Undergoing IVF/ICSI-ET Treatment: A Systematic Review and Meta-Analysis

Combined Treatment with Prednisone and Bromocriptine&nbsp;does not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles

Combined Treatment With Prednisone and Bromocriptine Does Not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles: a Retrospective Study

Contact Info

Product

Resources

About

Combined Treatment with Prednisone and Bromocriptine does not Influence the Pregnancy Outcome in Fresh Embryo Transfer Cycles